BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025

Core Insights - BridgeBio Pharma, Inc. is set to present significant findings related to its drug Acoramidis at the Heart Failure Society of America Annual Scientific Meeting 2025, highlighting its focus on genetic diseases [1][6]. Group 1: Clinical Presentations - A late-breaking clinical trial presentation will discuss the effect of Acoramidis on cardiovascular outcomes in patients with ATTR-CM, presented by Dr. Ahmad Masri on September 28 [2]. - An oral presentation will reveal that continuous treatment with Acoramidis significantly reduced the risk of all-cause mortality and cardiovascular-related hospitalization at month 42 for patients with transthyretin amyloidosis, presented by Dr. Lily Stern on September 27 [2]. Group 2: Poster Sessions - A poster session will present results showing that Acoramidis mitigates the rise in NT-proBNP levels compared to placebo in patients with variant transthyretin amyloid cardiomyopathy, presented by Dr. Nitasha Sarswat on September 27 [3]. - Another poster will discuss the effect of Acoramidis on cardiac conduction abnormalities in transthyretin amyloid cardiomyopathy, presented by Dr. Brett W. Sperry on September 27 [3]. - A poster will address state-level differences in the incidence of transthyretin amyloid cardiomyopathy among U.S. veterans after the introduction of disease-modifying therapy, presented by Dr. Sandesh Dev on September 28 [3]. Group 3: Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy associated with wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, aimed at reducing cardiovascular death and related hospitalizations [4]. Group 4: Safety Information - Adverse reactions reported for Attruby include diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation of the drug [5].